Multiple myelomaNCAMPrognostic factorCD56 or neural cell adhesion molecule (NCAM) is a membrane glycoprotein expressed on neural cells, muscle tissues and myeloma cells. Expression of CD56 has been studied in patients with multiple myeloma (MM) with controversial results. The scope of this study was...
Using MMRFBiolinks R-Package for Discovering Prognostic Markers in Multiple Myeloma 2022, Methods in Molecular BiologyMarzia Settino received her Master Degree in Computer Engineering from the University of Calabria. She currently is completing the final year as Ph.D. student in Biomarkers of Chronic...
while tailoring the treatment, predictive and prognostic biological markers, as well as geriatric/frailty assessments, are to be considered according to the recommendation of the International Myeloma Working Group (IMWG) [8]. Here, an overview of the clinical practice...
Analysis of the genomic landscape of multiple myeloma highlights novel prognostic markers and disease subgroups. Leukemia 32, 2604–2616 (2018). Article CAS PubMed PubMed Central Google Scholar Vij, R. et al. Deep sequencing reveals myeloma cells in peripheral blood in majority of multiple ...
prognosis biomarker Subjects Immunosuppression Interleukins Myeloma Prognostic markers This article is cited by Mass cytometry dissects T cell heterogeneity in the immune tumor microenvironment of common dysproteinemias at diagnosis and after first line therapies Taxiarchis V. Kourelis Jose C. Villasboas...
Serum free light chain measurement:This test measures the amount of light chain, a type of myeloma protein, in the blood. Prognostic indicators:Various blood tests are used to predict the outcome (prognosis) for an individual. Some of these are simple tests done in every laboratory; others are...
Autologous stem cell transplantation (ASCT) remains the mainstay of the treatment in newly diagnosed transplant-eligible multiple myeloma (MM) patients. This retrospective study was performed to investigate the potential prognostic markers which may modify transplant course in a total of 256 ASCT recipie...
Although novel agents have improved treatment outcomes, identification of markers that will enable clinicians to determine which treatment is most appropriate for high-risk patients following initial diagnosis represents an exciting frontier in the clinical management of multiple myeloma. Biomarkers based on...
Multiple Myeloma: Is MRD Status at 1 Year After Treatment Predictive of Survival? Results from the Prognostic Immunophenotyping in Myeloma Response (PRIMeR) study, reported in the Journal of Clinical Oncology by Marcelo C. Pasquini, MD, MS, and colleagues, found that undetectable measurable residual...
The purpose of this study is to identify prognostic markers and treatment targets using a clinically certified sequencing panel in multiple myeloma. We performed targeted sequencing of 578 individuals with plasma cell neoplasms using the FoundationOne He